UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000009491
Receipt number R000011151
Scientific Title Prospective study for Investigation and prevention for HBV reactivation
Date of disclosure of the study information 2020/12/31
Last modified on 2022/06/14 09:19:44

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Prospective study for Investigation and prevention for HBV reactivation

Acronym

HBV reactivation study

Scientific Title

Prospective study for Investigation and prevention for HBV reactivation

Scientific Title:Acronym

HBV reactivation study

Region

Japan


Condition

Condition

HBV carrier, Past HBV infection

Classification by specialty

Medicine in general Hepato-biliary-pancreatic medicine Hematology and clinical oncology
Clinical immunology Infectious disease

Classification by malignancy

Others

Genomic information

YES


Objectives

Narrative objectives1

Investigation for frequency of HBV reactivation. Evaluation for preventive effect of HBV related hepatitis by nucleotide analogue or HB vaccination.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Frequency of HBV reactivation

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Positive for HBsAg or anti-HBc, or anti-HBs

Key exclusion criteria

Drug allergy for entecavir or HB vaccine

Target sample size

500


Research contact person

Name of lead principal investigator

1st name Akihiro
Middle name
Last name Tamori

Organization

Osaka City University Graduate School of Medicine

Division name

Department of Hepatology

Zip code

5458585

Address

1-4-3, Asahimachi, Abeno-ku, Osaka

TEL

06-6645-3811

Email

atamori@med.osaka-cu.ac.jp


Public contact

Name of contact person

1st name Akihiro
Middle name
Last name Tamori

Organization

Osaka City University Graduate School of Medicine

Division name

Department of Hepatology

Zip code

5458585

Address

1-4-3, Asahimachi, Abeno-ku, Osaka 545-8585, JAPAN

TEL

06-6645-3811

Homepage URL


Email

atamori@med.osaka-cu.ac.jp


Sponsor or person

Institute

Department of Hepatology, Osaka City University Graduate School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Department of Hepatology, Osaka City University Graduate School of Medicine

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

The ethical committee, Osaka City University Graduate School of Medicine

Address

1-5-7, Asahimachi, Abeno-ku, Osaka

Tel

06-6646-6125

Email

ethics@med.osaka-cu.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 12 Month 31 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2012 Year 10 Month 30 Day

Date of IRB

2021 Year 06 Month 09 Day

Anticipated trial start date

2012 Year 12 Month 03 Day

Last follow-up date

2024 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

198 cohorts have been enrolled to the present study.


Management information

Registered date

2012 Year 12 Month 06 Day

Last modified on

2022 Year 06 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011151


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name